- Home
- TRVI vs NFJ Comparison
TRVI vs NFJ Comparison
Compare TRVI & NFJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRVI | NFJ |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | TRVI | NFJ |
|---|---|---|
| Price | $13.60 | $14.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $21.55 | N/A |
| AVG Volume (30 Days) | ★ 982.4K | 154.1K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.01% |
| EPS Growth | ★ 31.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.41 | $12.00 |
| 52 Week High | $16.12 | $15.13 |
Technical Indicators
Market Signals| Indicator | TRVI | NFJ |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 56.03 |
| Support Level | $13.12 | $12.71 |
| Resistance Level | $14.57 | N/A |
| Average True Range (ATR) | 0.53 | 0.20 |
| MACD | -0.11 | -0.03 |
| Stochastic Oscillator | 23.23 | 57.63 |
Price Performance
Historical ComparisonAbout TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. It pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.